RxDoctor Payments DataLook up a doctor →

Sanjiv Gupta, MD

Internal Medicine · Grayson, KYNPI 1487761243

Payments from drug & device makers

$51,402in general payments, 2019–2025

Across 625 payments — averaging $82.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$20K
  • Johnson & Johnson$18K
  • Novo Nordisk AS$3K
  • AbbVie$2K
  • GSK$911
  • Biofire Diagnostics, LLC$820
  • plus $6K from 43 others
$12,590in research payments, 2019–2025

Across 12 payments — averaging $1049.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$13K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk61$20,487
Johnson & Johnson34$18,316
Novo Nordisk AS3$2,800
AbbVie(2 entities)135$2,205
GSK44$911
Biofire Diagnostics, LLC2$820
Pfizer44$602
Bayer21$590
Abbott20$456
AstraZeneca(2 entities)31$452
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC25$376
Lilly USA, LLC22$341
Otsuka America Pharmaceutical, Inc.17$328
Amgen(2 entities)20$315
Merck19$290
Novartis19$285
Boehringer Ingelheim17$247
Radius Health, Inc.12$174
Biohaven Pharmaceuticals, Inc.11$155
Amarin Pharma, Inc.8$140
Exact Sciences6$120
Supernus Pharmaceuticals, Inc.5$94
Mylan Specialty L.p.5$91
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$81
E.r. Squibb & Sons, L.L.C.4$59
Xeris Pharmaceuticals, Inc.3$55
Takeda Pharmaceuticals U.S.A., Inc.4$55
Biohaven Pharmaceutical Holding Company Ltd.3$50
Shield Therapeutics Inc1$49
Dexcom, Inc.2$44
Smith+Nephew2$40
Daiichi Sankyo Inc.2$33
Axsome Therapeutics, Inc.1$33
Antares Pharma, Inc.2$31
Abiomed1$29
Kowa Pharmaceuticals America, Inc.2$27
Paratek Pharmaceuticals, Inc.1$25
Seqirus USA Inc1$20
Alkermes, Inc.1$19
Phathom Pharmaceuticals, Inc.1$18
Impel Pharmaceuticals Inc.1$17
Orexo US, Inc.1$17
Lundbeck LLC1$16
Teva Pharmaceuticals USA, Inc.1$16
Esperion Therapeutics, Inc.1$16
Corcept Therapeutics1$16
Braeburn Inc.1$15
Indivior Inc.1$13
Neuronetics, Inc.1$13

How this compares

$51,402 in reported general payments places this provider in the 95th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky →

Medicare billing

Part B allowed, 2024
$304,396
Medicare patients
229
Services billed
5,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Grayson

See the full list for Kentucky →

Where these figures come from

Is this you, or does something look wrong? →